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Purpose/Objective: To correlate the vaginal toxicity to 
vaginal surface EQD23Gy dose in two protracted brachytherapy 
(BT) schedules administered after surgery for endometrial 
carcinoma. 
Materials and Methods: 319 patients (p) with EC staged after 
surgery as 2009-Figo I-IIIC underwent radiotherapy. External 
beam irradiation (EBI) plus BT was considered for high risk 
and stages II-III p and BT alone for intermediate risk p. From 
2003 to 2007 the treatment schedule for 166p was 3 
fractions(f)/week(w) of 4-6Gy after EBI (Group-1: 125p) and 
4-6Gy in 6f/2w for BT alone (Group-2: 41p). From 2007 to 
2011 the daily dose schedule in 94/153p was 2f/w of 5-6Gy 
after EBI (Group-3) and 5-6Gy in 4f in BT treatment alone 
(Group-4: 59p). The mean EBI dose in Groups 1 and 3 was 
44Gy (43-50.4). BT was performed mainly using vaginal 
cylinders. The median active length of BT treatment was 
2.5cm (2-4). Toxicity was prospectively evaluated using the 
objective criteria of LENT-SOMA. In Groups 1+3: the sum of 
EBI+BT was performed for the EQD23Gy analysis. Statistics: 
Chi-square, Fisher and Student’s-t tests. 
Results: Stage: Group-1: 29-IA, 61-IB, 12-II, 10-IIIA, 2-IIIB, 9 
IIIC1, 2-IIIC2; Group-2: 24-IA, 16-IB, 1-II; Group-3: 5-IA, 45-IB, 
14-II, 13-IIIA, 2-IIIB, 10-IIIC1, 5-IIIC2; Group-4: 33-IA, 24-IB, 
2II. Mean follow-up: Group-1: 68.08 months (m) (7.73-
123.13); Group-2 63.41m (21.2-108.56); Group-3: 47.51m 
(8.64-82.14); Group-4: 48.08m (19.23-96.66). Median overall 
BT treatment time: Group-1: 5 days (d) (3-23); Group-2: 13d 
(8-28); Group-3: 2d (2-12); Group-4: 6d (4-15). 
Vaginal cuff relapses (VCR): 5/320p, 1.56%. Group-1: 3p; 
Group-2+4: 0p; Group-3: 2p. On comparing Groups-1+3 vs. 
Groups-2+4, the incidence of VCR was 2.28% vs. 0% 
respectively (p=0.320). Late Toxicity: 1-Vagina: Group-1: 
20.8% G1-2; 0.8% G4. Group-2: 24.4%; Group-3: 26.6% G1-2; 
1.1% G4. Group-4: 20.0% G1-2. No differences were found 
between the two treatment schedules (p= 0.680) and 
between Groups-1+3 vs. Groups-2+4 (p= 0.667). The overall 
percentage of G1-G4 toxicity for Groups 1-4: 23.4%. Mean 
vaginal surface EQD23Gy: Groups 1+3: 90.02Gy, SD 13.72; 
Groups 2+4: 79.83Gy, SD 23.66; significant differences in 
EQD2 values were found between Groups 1+3 and 2+4 
(p<0.0001). Nevertheless, no correlation was found between 
the vaginal surface EQD23Gy and the development of vaginal 
complications.  
Conclusions: No differences were found in VCR and toxicity 
between the 2 BT schedules. No correlation was found 
between vaginal toxicity and vaginal surface EQD23Gy for the 
present dose per fraction schedules.  
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Purpose/Objective: From May 2010 all cervical cancer 
patients (pts) referred for brachytherapy (BT) have been MRI 
scanned. We present our retrospectively evaluated treatment 
results with gradually introduction of individualised MR-based 
plans. 
Materials and Methods: All pts referred for BT were filed in a 
separate database. Pts characteristics, morbidity and 
pathology and imaging data were obtained from the 
electronic charts. Survival data were obtained through the 
national patient registry. The radiation doses were drawn 
from Eclipse™ for the external radiation treatment (EBRT) 
and from Oncentra™ for BT. All EBRT were IMRT or rapid arc. 
BT was delivered as HDR, with a Vienna applicator, a 
Titanium Cylinder Applicator or a Steel Cylinder Applicator. 
In addition to and MRI at diagnosis, before BT and at the first 
BT fraction (F), the pts were scheduled to have a conebeam 
CT (CBCT) scan on the treatment couch at each fraction. A 
modified Embrace CRF was the basis of data collection. Data 
were processed with SPSS Predictive Analytics-software. 
Survival was calculated using the Kaplan-Meier estimate with 
a log rank test for significance. 
Results: We treated 80 pts from May 2010 to August 2014 
with the following characteristics; Median age 53.5 years [21-
83], PS0: 76.3% , PS1: 20%, PS≥2: 3.8%, stage I: 12.5%, stage 
II: 71.3%, stage ≥III: 16.3%, Histology: Squamous Cell 
Carcinoma 78.8%, Adenocarcinoma 17.5%, Small Cell 
Carcinoma 3.8%, 25% were treated as N+ disease, of these 
were 35% were bioptically verified. The EBRT PTV-T dose was 
45Gy, 50Gy or 60Gy to respectively 1.3%, 53.5% and 46.3% of 
the pts. The doses to the PTV-E were accordingly 0Gy, 45Gy 
and 49.5Gy. PTV-N was doses to 64 Gy in all cases. All but 
one pt were MRI scanned before EBRT and before BT. Planned 
BT dose was 5Gy in 5F for all pts., of those 56.3% were 
treated with a standard plan and 43.8% with a modified plan, 
from October 2012 all had modified plans. The calculated 
median dose, based on MRI before BT or MRI with applicator 
to HR-CTV90 was 104.9Gy [70.9-168.1Gy] and 96.6Gy [66.4-
146.8Gy] to HR-CTV95. The median follow up period was 29.3 
months. The pelvic control rate was 92.5%, with 3.7% failures 
inside the BT target volume. The overall survival at 4 years 
was 72.5% and significant related to Stage and nodal status, 
se figure 1. We identified 41 pts with grade 2 or more toxicity 
(tox), of these 21 pts had gastrointestinal tox, 22 had 
urological tox and 22 had vaginal tox. Some pts had tox from 
more than one organ system. 
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Conclusions: The introduction of MRI based BT in our clinic 
was feasible and the treatment results were similar to other 
published series. The rate of significant side effects 
encourages us to elaborate the plan modification techniques, 
apply interstitial needles and treat all pts with individual 
plan in the future. 
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Purpose/Objective: Contouring the bowel is one of the most 
time consuming aspects of planning a HDR treatment of the 
cervix. This investigates the possibility of reducing the 
volume of bowel to be contoured for planning purposes when 
treating the Cervix with HDR using a Tandem and Ovoid 
Applicator with CT simulation. It is hoped that the service 
efficiency can be improved by reducing the volume of bowel 
contoured prior to planning. 
Materials and Methods: Additional contours were 
constructed on previous patient plans which were clinically 
accepted. Using Oncentra Brachy (Version 4.3), 3D margins of 
0.5cm, 1.0cm, 1.5cm and 2.0cm were grown around the HR-
CTV. The overlap of the original (complete) bowel volume 
and the newly created volumes was extracted to produce a 
bowel contour which was limited to within a given distance 
from the HR-CTV. For example, taking the intersection of the 
‘Bowel’ and the ‘HRCTV + 1.0cm’ to give a bowel contour 
which only extends to 1.0cm beyond the HR-CTV (referred to 
as ‘HR-CTV + 1.0cm & Bowel’) This produced a set of bowel 
outlines which were limited to within a given margin of the 
HR-CTV. The dosimetric parameters (D2cc, D1cc, D0.1cc) 
reported by Oncentra were recorded for the original bowel 
volume, as well as the limited bowel volumes produced to 
enable comparison. 
Results: A total of 10 plans were contoured and assessed, 
with comparison of the dosimetric parameters performed for 
the limited bowel volumes. A summary of the results is given 
in the table. The mean doses for the fully contoured bowel 
were 3.99Gy, 4.39Gy and 5.37Gy for the D2cc, D1cc and 
D0.1cc respectively . When the bowel was limited to within 
1.5cm or less of the HR-CTV there was at least one contour 
which did not give sufficient volume to produce complete 
dose statistics. When considering contouring within a 2.0cm 
margin of the HR-CTV the mean change in the D0.1cc was 
less than 0.1Gy (with D2cc and D1cc being less than 0.05Gy). 
The reduction in volume contoured however was large, with a 
reduction of around 65% in volume when restricting 
contouring to within 2.0cm of the HR-CTV. 
 
 
Conclusions: Restricting the bowel contouring for planning of 
treatments of the Cervix using Tandem and Ovoid applicators 
with CT simulation to within 2.0cm of the HR-CTV has the 
potential to reduce the volume contoured by 65%. This 
results in a change in reported dose statistics of less than 
0.1Gy for the D0.1cc and less than 0.05Gy for the D1cc and 
D2cc. These small changes would not have an effect on the 
clinical decision to treat using the produced plans. 
By producing a an expanded HR-CTV contour, the bowel 
contouring could be easily limited to within this region, thus 
reducing the time taken to contour, ultimately leading to a 
more efficient treatment delivery. Applying this to other 
organs at risk may also be possible. 
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Purpose/Objective: Aim of this study was to evaluate vaginal 
recurrence rate and toxicity after postoperative vaginal 
brachytherapy (VBT) in patients (pts) with early stage 
endometrial cancer.  
